Janus Kinase Inhibitors: all 1,428 studies that test it

Page 6 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisCompletedNCT03733301Phase 3Results posted
• PF-06651600 for the Treatment of Alopecia AreataCompletedNCT03732807Phase 2/3Results posted
• Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedNCT03725722Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisCompletedNCT03725202Phase 3Results posted
• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedNCT03721965Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results posted
• A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsCompletedNCT03715829Phase 2Results posted
• Topical Ruxolitinib Lichen PlanusCompletedNCT03697460Phase 2Results posted
• Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingNCT03697408Phase 1/2Results posted
• Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaCompletedNCT03683719Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisCompletedNCT03682705Phase 2Results posted
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.CompletedNCT03675477Phase 2Results posted
• A Renal Impairment Study for PF-04965842CompletedNCT03660241Phase 1Results posted
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingNCT03654768Phase 2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• Efficacy and Safety of TD-1473 in Crohn's DiseaseTerminatedNCT03635112Phase 2Results posted
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 3Results posted
• A Hepatic Impairment Study for PF-04965842.CompletedNCT03626415Phase 1Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)CompletedNCT03616964Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusTerminatedNCT03616912Phase 3Results posted
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic GlucocorticoidsCompletedNCT03616184Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03607487Phase 2Results posted
• A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)CompletedNCT03607422Phase 3Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedNCT03585296Phase 2Results posted
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedNCT03584516Phase 2/3Results posted
• Tofacitinib for Inflammatory Eye DiseaseStatus unknownNCT03580343Phase 2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03575871Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia AreataCompletedNCT03570749Phase 2/3Results posted
• A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03569371Phase 2Results posted
• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)CompletedNCT03569293Phase 3Results posted
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruitingNCT03568318Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03559270Phase 3Results posted
• Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedNCT03551821Phase 2Results posted
• Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)CompletedNCT03502616Phase 3Results posted
• A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedNCT03495817Phase 2Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisCompletedNCT03486457Phase 3Results posted
• A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedNCT03468855Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03435081Phase 3Results posted
• A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically AdvisableCompletedNCT03428100Phase 3Results posted
• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.CompletedNCT03427866Phase 2Results posted
• Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionCompletedNCT03417778Phase 1Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedNCT03395184Phase 2Results posted
• A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataTerminatedNCT03354637Phase 2Results posted
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03349060Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic TherapiesCompletedNCT03345849Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyCompletedNCT03345836Phase 3Results posted
• A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisCompletedNCT03334435Phase 3Results posted
• Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334422Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334396Phase 3Results posted
• Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)CompletedNCT03315689Phase 2Results posted
• Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With LupusCompletedNCT03288324Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)CompletedNCT03285711Phase 2Results posted
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionTerminatedNCT03281304Phase 4Results posted
• Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)CompletedNCT03274076Phase 1/2Results posted
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCompletedNCT03252587Phase 2Results posted
• A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisCompletedNCT03222609Phase 2Results posted
• A Study of Baricitinib in Healthy ParticipantsCompletedNCT03212638Phase 1Results posted
• A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque PsoriasisCompletedNCT03210961Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTerminatedNCT03207815Phase 2Results posted
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing SpondylitisCompletedNCT03178487Phase 2Results posted
• Ruxolitinib in Operable Head and Neck CancerTerminatedNCT03153982Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedNCT03139604Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataCompletedNCT03137381Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)CompletedNCT03134222Phase 2Results posted
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)TerminatedNCT03123588Phase 2Results posted
• VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerActive, not recruitingNCT03120624Phase 1Results posted
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedNCT03112603Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeCompletedNCT03100942Phase 2Results posted
• A Study of INCB018424 Phosphate Cream in Subjects With VitiligoCompletedNCT03099304Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's DiseaseCompletedNCT03077412Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)CompletedNCT03046056Phase 2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• Baricitinib in Relapsing Giant Cell ArteritisCompletedNCT03026504Phase 2Results posted
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompletedNCT03025308Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic DermatitisCompletedNCT03011892Phase 2Results posted
• A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIACompletedNCT03000439Phase 3Results posted
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedNCT02974868Phase 2Results posted
• Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To MethotrexateCompletedNCT02969044Phase 2Results posted
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT02969018Phase 2Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02958865Phase 2Results posted
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)CompletedNCT02955212Phase 3Results posted
• A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)CompletedNCT02953678Phase 2Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• Ruxolitinib for Premalignant Breast DiseaseCompletedNCT02928978Phase 2Results posted
• A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisCompletedNCT02925117Phase 2Results posted
• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3Results posted
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3Results posted

← Janus Kinase Inhibitors overview